EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Rift Valley fever (RVF) vaccine candidate 40Fp8 shows an extreme attenuation in IFNARKO mice following intranasal inoculation

Belén Borrego iD, Celia Alonso, Sandra Moreno, Nuria de la Losa, Pedro José Sánchez-Cordón, Alejandro Brun

PLOS Neglected Tropical Diseases · 2024

DOI: 10.1371/journal.pntd.0012011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2024. Verfasst von Belén Borrego und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of IMMUNOLOGY, PATHOLOGY AND CONTROL OF INFECTIOUS DISEASES, Centro de Investigación en Sanidad Animal CISA INIA/CSIC, Valdeolmos, Madrid,…. Hauptthemen laut MEDLINE: Rift Valley Fever, Vaccines, Attenuated, Rift Valley fever virus, Viral Vaccines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación, European Union Next Generation EU/PRTR, MCIN/AEI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rift Valley fever (RVF) is an important zoonotic viral disease affecting several species of domestic and wild ruminants, causing major economic losses and dozens of human deaths in various geographical areas of Africa, where it is endemic. Although it is not present in Europe, there is a risk of its introduction and spread linked to globalisation and climate change. At present, the only measure that could help to prevent the disease is vaccination of flocks in areas at risk of RVF. Available live attenuated vaccines are an effective means of controlling the disease, but their use is often questioned due to residual virulence, particularly in susceptible hosts such as pregnant sheep. On the other hand, no vaccine is currently licensed for use in humans. The development of safe and effective vaccines is therefore a major area of research. In previous studies, we selected under selective mutagenic pressure a highly attenuated RVFV 56/74 virus variant called 40Fp8. This virus showed an extremely attenuated phenotype in both wild-type and immunodeficient A129 (IFNARKO) mice, yet was still able to induce protective immunity after a single inoculation, thus supporting its use as a safe, live attenuated vaccine. To further investigate its safety, in this work we have analysed the attenuation level of 40Fp8 in immunosuppressed mice (A129) when administered by the intranasal route, and compared it with other attenuated RVF viruses that are the basis of vaccines in use or in development. Our results show that 40Fp8 has a much higher attenuated level than these other viruses and confirm its potential as a candidate for safe RVF vaccine development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rift Valley FeverVaccines, AttenuatedRift Valley fever virusViral VaccinesAdministration, IntranasalAnimalsMiceFemaleVaccinationAntibodies, Viral

Substanzen

Vaccines, AttenuatedViral VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Department of IMMUNOLOGY, PATHOLOGY AND CONTROL OF INFECTIOUS DISEASES, Centro de Investigación en Sanidad Animal CISA INIA/CSIC, Valdeolmos, Madrid, Spain.
  • Department of INFECTIOUS DISEASES AND GLOBAL HEALTH, Centro de Investigación en Sanidad Animal CISA INIA/CSIC, Valdeolmos, Madrid, Spain.

ORCID-Profile: Belén Borrego

Förderung

  • Ministerio de Ciencia e Innovación
  • European Union Next Generation EU/PRTR
  • MCIN/AEI
  • European Regional Development Fund

Zitieren

APA

Borrego, B., Alonso, C., Moreno, S., de la Losa, N., Sánchez-Cordón, P. J., & Brun, A. (2024). The Rift Valley fever (RVF) vaccine candidate 40Fp8 shows an extreme attenuation in IFNARKO mice following intranasal inoculation. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0012011

Vancouver

Borrego B, Alonso C, Moreno S, de la Losa N, Sánchez-Cordón PJ, Brun A. The Rift Valley fever (RVF) vaccine candidate 40Fp8 shows an extreme attenuation in IFNARKO mice following intranasal inoculation. PLOS Neglected Tropical Diseases. 2024. doi:10.1371/journal.pntd.0012011

BibTeX
@article{Borrego2024,
  author = {Borrego, Belén and Alonso, Celia and Moreno, Sandra and de la Losa, Nuria and Sánchez-Cordón, Pedro José and Brun, Alejandro},
  title = {The Rift Valley fever (RVF) vaccine candidate 40Fp8 shows an extreme attenuation in IFNARKO mice following intranasal inoculation},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2024},
  doi = {10.1371/journal.pntd.0012011}
}
Kostenlos starten →